133 related articles for article (PubMed ID: 32799198)
1. IgA Nephropathy Associated with Trifluridine/Tipiracil: A Case Report.
Desbuissons G; Ngango L; Brochériou I; Fournier P
Nephron; 2020; 144(10):506-508. PubMed ID: 32799198
[TBL] [Abstract][Full Text] [Related]
2. Leukocytoclastic vasculitis with late-onset Henoch-Schönlein purpura after trifluridine/tipiracil treatment.
Aria AB; Chen L; Glass WF; Lahoti A; Chon SY
Dermatol Online J; 2018 Oct; 24(10):. PubMed ID: 30677817
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.
Cleary JM; Rosen LS; Yoshida K; Rasco D; Shapiro GI; Sun W
Invest New Drugs; 2017 Apr; 35(2):189-197. PubMed ID: 28111727
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil.
Michl GM; Vogt FM; Nouriani A; Ladurner R; Kremer M; Reisländer T; Michl M
Chemotherapy; 2024; 69(1):27-34. PubMed ID: 37336201
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers.
Takahashi M; Sakamoto Y; Ohori H; Tsuji Y; Kuroki M; Kato S; Otsuka K; Komine K; Takahashi M; Takahashi S; Shirota H; Ouchi K; Takahashi Y; Imai H; Shibata H; Yoshioka T; Tanaka M; Yamaguchi H; Yamaguchi T; Shimodaira H; Ishioka C
Cancer Chemother Pharmacol; 2021 Sep; 88(3):393-402. PubMed ID: 34028598
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
Signorelli C; Gemma D; Grande R; DE Marco S; Saltarelli R; Morandi MG; Spinelli GP; Zoratto F; Sperduti I; Chilelli MG; Ceribelli A; Ruggeri EM
Anticancer Res; 2021 May; 41(5):2553-2561. PubMed ID: 33952483
[TBL] [Abstract][Full Text] [Related]
8. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
Saif MW; Becerra CR; Fakih MG; Sun W; Popovic L; Krishnamurthi S; George TJ; Rudek MA; Shepard DR; Skopek J; Sramek V; Zaric B; Yamamiya I; Benhadji KA; Hamada K; He Y; Rosen L
Cancer Chemother Pharmacol; 2021 Sep; 88(3):485-497. PubMed ID: 34097100
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
[TBL] [Abstract][Full Text] [Related]
11. Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
Stavraka C; Pouptsis A; Synowiec A; Angelis V; Satterthwaite L; Khan S; Chauhan M; Holden C; Young S; Karampera C; Martinou M; Mills-Baldock T; Baxter M; Barry A; Eccles B; Iveson T; Shiu KK; Hill M; Abdel-Raouf S; Graham JS; Thomas A; Ross PJ
Clin Colorectal Cancer; 2021 Dec; 20(4):342-349. PubMed ID: 34696965
[TBL] [Abstract][Full Text] [Related]
12. Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer.
Barone C; Bartolomeo MD; Lonardi S; Maiello E; Martinelli E; Moretto R; Strippoli A; Tamburini E; Zaniboni A; Pinto C
Future Oncol; 2021 May; 17(14):1749-1759. PubMed ID: 33464133
[TBL] [Abstract][Full Text] [Related]
13. Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani J
Clin Colorectal Cancer; 2022 Jun; 21(2):e145-e147. PubMed ID: 34969632
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.
Uboha NV; Lubner SJ; LoConte NK; Mulkerin DL; Eickhoff JC; Deming DA
Invest New Drugs; 2020 Oct; 38(5):1520-1525. PubMed ID: 32253554
[TBL] [Abstract][Full Text] [Related]
16. [
Kim SY; Jung JH; Lee HJ; Soh H; Lee SJ; Oh SJ; Chae SY; Lee JH; Lee SJ; Hong YS; Kim TW; Moon DH
Cancer Res; 2017 Dec; 77(24):7120-7130. PubMed ID: 29055019
[TBL] [Abstract][Full Text] [Related]
17. Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.
Peeters M; Cervantes A; Moreno Vera S; Taieb J
Future Oncol; 2018 Jul; 14(16):1629-1645. PubMed ID: 29701076
[TBL] [Abstract][Full Text] [Related]
18. The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
Sousa MJ; Gomes I; Pereira TC; Magalhães J; Basto R; Paulo J; Jacinto P; Bonito N; Sousa G
Cancer Treat Res Commun; 2022; 31():100531. PubMed ID: 35172243
[TBL] [Abstract][Full Text] [Related]
19. Integrated safety summary for trifluridine/tipiracil (TAS-102).
Falcone A; Ohtsu A; Van Cutsem E; Mayer RJ; Buscaglia M; Bendell JC; Kopetz S; Bebeau P; Yoshino T
Anticancer Drugs; 2018 Jan; 29(1):89-96. PubMed ID: 29176395
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
Bullement A; Underhill S; Fougeray R; Hatswell AJ
Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
